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We are grateful to Mr Trauernicht and Dr du Toit for their 
letter to the editor written on the recently published South 
African practice guidelines on peptide radionuclide therapy 
of neuroendocrine tumors.1 In the letter, they express concern 
that internal dosimetry was discussed in “only a single short 
paragraph” and that this may create an impression that 
“internal dosimetry assessment is just an optional extra.” The 
authors drew a contrast between the South African guidelines 
and the joint International Atomic Energy Agency (IAEA), 
European Association of Nuclear Medicine (EANM) and 
the Society of Nuclear Medicine and Molecular Imaging 
guidelines published earlier where “a whole section on 
dosimetry” was included.2
The NETTER-1 trial is a phase III trial that demonstrated 
the superiority (regarding survival benefits) of peptide 
receptor radionuclide therapy (PRRT) of well-differentiated 
metastatic midgut neuroendocrine tumours (NETs) using 
Lu-177 DOTATATE over long-acting octreotide alone.3 
Following the report of this trial, many regulatory authorities 
around the world approved the use of this radionuclide therapy 
option in routine clinical practice. Consequently, the demand 
by patients and their oncologists for this highly effective 
therapy with tolerable side effects increased tremendously in 
South Africa and elsewhere around the world. In response to 
this high demand, the College of Nuclear Physicians (CNP) 
of South Africa, on behalf of the South African Society 
of Nuclear Medicine (SASNM), came together to publish 
practice guidelines to “assist Nuclear Medicine Physicians in 
the evaluation, safe administration and follow-up (assessment 
of response and long-term toxicities) of patients with NETs 
referred for or considered for PRRT”.1
Our intervention (the practice guidelines) was to provide 
an essential guide with everyday applicability for Nuclear 
Physicians to safely apply PRRT in patients’ management 
with consideration of the opportunities and challenges for 
such application in South Africa and similar climes across 
the world. The practice guidelines were not meant to be 
a complete and exhaustive step-by-step approach to the 
application of PRRT. Details regarding quality control, post-
therapy imaging, dosimetry, and other such matters were 
not included to allow practitioners some flexibility in the 
application of this guidance document. Our brief mention of 
dosimetry must not be misconstrued as indicating that it is 
not an important exercise or that it be regarded as an optional 
extra. A similar approach to ours has been adopted in other 
guidelines produced by other international organisations for 
radionuclide imaging and therapy.4,5 
Dosimetry ensures that a lethal dose is delivered to the 
tumour while keeping radiation exposure to normal organs 
within safe limits. It is a useful step in radionuclide therapy 
for safety and efficacy. Its practice has got several challenges, 
however. As affirmed by Trauernicht and du Toit, it is difficult 
to perform, and the skills required for its performance are not 
uniformly available in all practices. There are several methods 
for the performance of dosimetry assessment which vary in 
sophistication. OLINDA is a useful software application 
to estimate the mean absorbed dose to tumours and normal 
organs, such as bone marrow and kidneys, in PRRT. In 
recognising the challenges with dosimetry assessment, the 
joint IAEA, EANM and SNMMI guidelines recommend that 
patient-specific dosimetry be performed "if feasible".2
A local South African experience and several international 
studies have reported on the safety and efficacy of PRRT in 
large patient populations with long-term follow-up treated for 
NETs.6-9 Adhering to practices reported in these studies ensures 
safe and effective administration of PRRT. Radioiodine 
treatment of well-differentiated thyroid cancer is the oldest 
and most commonly applied radionuclide therapy modality 
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in clinical practice. Decades of use have allowed a clear 
identification of a patient sub-population in which dosimetry 
is essential for therapy effectiveness and the limitation of 
therapy-related adverse effects.10 Such experience is, however, 
lacking for PRRT and it is consequently unknown for which 
groups of patients sophisticated individualised dosimetry may 
be mandatory.
In conclusion, PRRT administration requires the expertise 
of many professionals including the medical physicist, 
who, by regulation, must observe all radionuclide therapy 
administrations. Dosimetry is a responsibility of the medical 
physicist. Despite challenges to its practice, dosimetry 
is an essential step in radionuclide therapy planning and 
administration. Where the expertise is available and when 
feasible, dosimetry must be done in all patients to obtain an 
estimate of the tumour dose, and the mean absorbed dose 
to normal organs especially bone marrow and the kidneys. 
Furthermore, in centres without the expertise for this 
assessment, every effort must be made to ensure that it be put 
in place. We hope to include a section detailing dosimetry 
assessment in the second version of these practice guidelines 
planned for the near future.
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